Application 211780
- Type
- ANDA
- Sponsor
- PADAGIS US
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | SUCRALFATE | SUCRALFATE | SUSPENSION;ORAL | 1GM/10ML | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A211780-001 | SUCRALFATE | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A211780-001 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | 6a471c1ec25d… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211780-001 | SUCRALFATE | 1GM/10ML | SUSPENSION / ORAL | AB | 2025-04-14 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A211780-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A211780-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A211780-001 | AB | 1 | 6a471c1ec25d… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A211780-001 | AB | 1 | a50c72e98297… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sucralfate | SUCRALFATE | Safecor Health, LLC | 526f6ebc-557c-4c53-8118-1907baa0820a | 2026-07-16 | Warnings, Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 1eb38f64-4d5a-46e6-a030-057beece5e44 | 2026-07-10 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | Chartwell RX, LLC | 30c0965a-02a0-46b5-aa09-3f5fb5047b22 | 2026-07-06 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | NCS HealthCare of KY, LLC dba Vangard Labs | 3b0259fa-806f-44c1-8deb-c11dbd84582d | 2026-06-24 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | ASCLEMED USA INC. | cd25eb96-29ea-48b2-bdee-c2ea98f216b8 | 2026-05-18 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | Safecor Health LLC | 1a6d96f2-fe1f-4aaf-8520-616973c224aa | 2026-04-07 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | Cardinal Health 107, LLC | 92c8672a-c6b8-4ec8-a815-c30bdd960ac7 | 2026-03-30 | Warnings, Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | PAI Holdings, LLC dba PAI Pharma | 113a068a-2ce9-421c-8b89-87ce30e19225 | 2026-03-11 | Warnings, Adverse reactions | Sucralfate SUCRALFATE |
| sucralfate | SUCRALFATE | Strides Pharma Science Limited | 8e25bff2-769e-4bd4-a6de-895c58b840d2 | 2026-03-10 | Warnings, Adverse reactions | sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE ORAL SUSPENSION | Major Pharmaceuticals | 98a8fedd-fa06-416a-8a85-b899631978f9 | 2026-02-11 | Warnings, Adverse reactions | Sucralfate |
| Sucralfate | SUCRALFATE | Preferred Pharmaceuticals Inc | a434bf8f-cc60-4d84-a9a4-61c3ff6b700e | 2026-01-21 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | AvKARE | 0909acc5-c746-17fb-e063-6394a90a677f | 2026-01-19 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate oral suspension | SUCRALFATE | Glenmark Pharmaceuticals Inc., USA | 1e595c2a-edd0-43f7-a2db-69553b9557d9 | 2026-01-06 | Warnings, Adverse reactions | SUCRALFATE |
| Sucralfate | SUCRALFATE | Northwind Health Company, LLC | f3095db3-fd02-873c-e053-2a95a90a5b1f | 2026-01-01 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE ORAL | Cardinal Health 107, LLC | a0c9f585-1007-4996-aef7-e17cd55d28cd | 2025-12-31 | Warnings, Adverse reactions | Sucralfate |
| Sucralfate | SUCRALFATE ORAL | TruPharma, LLC | 7d441128-45d2-4bf2-817b-665784992e90 | 2025-12-29 | Warnings, Adverse reactions | Sucralfate |
| Sucralfate | SUCRALFATE | Northwind Health Company, LLC | 464bf611-4dbb-4707-b9dd-39ca178ed4bf | 2025-12-26 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE | Redpharm Drug | 3251e156-4c52-63b3-e063-6294a90a9a95 | 2025-12-18 | Adverse reactions | Sucralfate SUCRALFATE |
| Sucralfate | SUCRALFATE ORAL | AvKARE | c019bf24-8273-8d2f-e053-2a95a90aec98 | 2025-12-03 | Warnings, Adverse reactions | Sucralfate |
| Sucralfate | SUCRALFATE ORAL | AvPAK | e78ef7d4-faa7-aebf-e053-2995a90a6f84 | 2025-12-03 | Warnings, Adverse reactions | Sucralfate |